Skip to Main Content
Abbreviations
++

Table Graphic Jump Location
Favorite Table | Download (.pdf) | Print
ABVD adriamycin, bleomycin, vinblastine and dacarbazine
ACA additional chromosome abnormalities
ACD anaemia of chronic disease
ACS acute chest syndrome
ADP adenosine diphosphate
AIHA autoimmune haemolytic anaemia
ALG antilymphocyte globulin
ALL acute lymphoblastic leukaemia
alloBMT allogeneic bone marrow transplantation
alloSCT allogeneic stem cell transplantation
ALT alanine transferase
AML acute myeloid leukaemia
ANA antinuclear antibody
ANC absolute neutrophil count
APA antiphospholipid antibodies
APC activated protein C
APS antiphospholipid syndrome
APTT activated partial thromboplastin time
ARDS adult respiratory distress syndrome
ASCT autologous stem cell transplantation
ATG antithymocyte globulin
AVN avascular necrosis
BCSH British Committee for Standards in Haematology
BEACOPP bleomycin, etoposide, adriamycin [doxorubicin], cyclophosphamide, vincristine, procarbazine and prednisolone
BEAM carmustine, etoposide, cytarabine and melphalan
BMT bone marrow transplantation
CALGB Cancer and Leukemia Group B
CAP cyclophosphamide, adriamycin [doxorubicin] and prednisolone
CCyR complete cytogenetic response
2-CDA 2-chlorodeoxyadenosine (cladribine)
CEL chronic eosinophilic leukaemia
ChlVPP chlorambucil, vinblastine, procarbazine and prednisolone
CHOP cyclophosphamide, adriamycin [doxorubicin], vincristine and prednisolone
CHR complete haematologic response
CIMF chronic idiopathic myelofibrosis
CLL chronic lymphocytic leukaemia
CML chronic myeloid leukaemia
CN cytogenetically normal
CNS central nervous system
COPPABVD cyclophosphamide, vincristine, procarbazine, prednisolone and ABVD
CPHPC R-1-[6-[R-2-carboxy-pyrrolidin-1- yl]-6-oxo-hexanoyl]pyrrolidine-2-carboxylic acid
CR complete remission/complete response
CR1 first complete remission
CRAB hyperCalcaemia, Renal dysfunction, Anaemia, Bone fractures or lytic lesions
CSA ciclosporin
CSF cerebrospinal fluid
CSSCD Cooperative Study of Sickle Cell Disease
CT computed tomography
CVP central venous pressure
CVP cyclophosphamide, vincristine and prednisolone
CXR chest X-ray
CyR cytogenetic response
DCT direct Coombs’ test
DDAVP 1-deamino-8-D-arginine vasopressin
DEXA dual-energy X-ray absorptiometry
DFS disease-free survival
DIC disseminated intravascular coagulation
DLBCL diffuse large B-cell non-Hodgkin lymphoma
DVT deep vein thrombosis
EBMT European Blood and Marrow Transplantation
EDTA ethylenediaminetetraacetic acid
EFS event-free survival
EMEA European Medicines Agency
EP extramedullary plasmacytomas
EPO erythropoietin
ESP erythropoiesis-stimulating protein
ESR erythrocyte sedimentation rate
ET essential thrombocythaemia
FAB French–American–British
FBC full blood count
FC fludarabine combined with cyclophosphamide
FDG-PET 18F-fluoro-deoxyglucose positron emission tomography
FFP fresh frozen plasma
FI full intensity
FISH fluorescent in situ hybridization
FIX factor IX
FL follicular lymphoma
FLC free light chain
FLIPI Follicular Lymphoma International Prognostic Index
FNA fine needle aspirate
FV factor V
FVIII factor VIII
FX factor X
FXI factor XI
G-CSF granulocyte colony-stimulating factor
GFR glomerular filtration rate
GI gastrointestinal
GIFAbs growth inhibitory factor antibodies
GP General Practitioner
GPI glycosyl phosphatidyl inositol
GvHD graft-versus-host disease
GvL graft-versus-leukaemia
GvM graft-versus-myeloma
Hb haemoglobin
HbF haemoglobin F
HbS haemoglobin S
HCT haematocrit
HDAC histone deacetylase
HDMTX high-dose methotrexate
HES hypereosinophilic syndrome
HIT heparin-induced thrombocytopenia
HIV human immunodeficiency virus
HLA human leukocyte antigen
HNA human neutrophil antigen
HPA human platelet antigen
HR haematologic response
HU hydroxyurea
HUS haemolytic uremic syndrome
ICH intracranial haemorrhage
IFRT involved field radiotherapy
Ig immunoglobulin
IL interleukin
IMF idiopathic myelofibrosis
IMiD immunomodulatory drug
INR International Normalized Ratio
IPI International Prognostic Index
IPSS International Prognostic Scoring System
IR imatinib-responsive
ITD internal tandem duplication
ITP idiopathic thrombocytopenic purpura
ITU intensive therapy unit
IV intravenous
JVP jugular venous pressure
LDH lactate dehydrogenase
LMWH low-molecular-weight heparin
LPD lymphoproliferative disease
LVF left ventricular failure
M4Eo acute myeloid leukaemia with eosinophilia
MCH mean corpuscular haemoglobin
MCHC mean corpuscular haemoglobin concentration
MCV mean cell volume
MDS myelodysplastic syndrome
β2-MG β2-microglobulin
MGUS monoclonal gammopathy of undetermined significance
MmolR major molecular response
MP melphalan and prednisone
MPL thrombopoietin receptor
MR minimal response
MRC Medical Research Council
MRD minimal residual disease
MRI magnetic resonance imaging
MSH Multicenter Study of Hydroxyurea in Sickle Cell Anemia
MT massive transfusion
MUD matched unrelated donor
nCR near-complete response
NHL non-Hodgkin lymphoma
NPM nucleophosmin
OS overall survival
PBSC peripheral blood stem cell
PBSCT peripheral blood stem cell transplantation
PCI protein creatinine index
PCM plasma cell myeloma
PCNSL primary central nervous system lymphoma
PCR polymerase chain reaction
PCyR partial cytogenetic response
PEG polyethylene glycol
PET positron emission tomography
PFA platelet function analyser
PMF primary myelofibrosis
PNH paroxysmal nocturnal haemoglobinuria
PR partial remission/partial response
PSA polysialic acids
PT prothrombin time
PTD partial tandem duplication
PV polycythaemia vera
RA refractory anaemia
RARS refractory anaemia with ringed sideroblasts
RBC red blood cell
RCT randomized controlled trial
rFVIIa recombinant factor VIIa
rhEPO recombinant human erythropoietin
RIC reduced-intensity conditioning
ROTI myeloma-related organ and/or tissue impairment
RT–PCR reverse transcription–polymerase chain reaction
SAP serum amyloid P
SBP solitary bone plasmacytomas
SC subcutaneous
SCD sickle cell disease
SCT stem cell transplantation
SHOT Serious Hazards of Transfusion
sIg surface immunoglobulin
SLE systemic lupus erythematosis
SM systemic mastocytosis
SVCO superior vena cava obstruction
TACO transfusion associated circulatory overload
TBI total body irradiation
TEDS thromboembolic deterrent stockings
TF tissue factor
TIPSS transjugular intrahepatic portosystemic shunt
TKI tyrosine kinase inhibitor
TOPPS Trial of Platelet Prophylaxis
TRALI transfusion-related acute lung injury
TRM transplant-related mortality
TT thrombin time
TTP thrombotic thrombocytopenic purpura
UCB umbilical cord blood
UFH unfractionated heparin
VAD vincristine, adriamycin (doxorubicin) and dexamethasone
VBMCP vincristine, carmustine, melphalan, cyclophosphamide and prednisone
vCJD variant Creutzfeldt Jacob Disease
VKOR vitamin K epoxide reductase
VTE venous thromboembolism
VWF von Willebrand factor
WBC white blood cell
WBRT whole brain radiotherapy
WCC white cell count
WHO World Health Organization
WM Waldenström’s macroglobulinaemia
ZPI protein Z-dependent protease inhibitor

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.